Entero Therapeutics files Q1 2024 pro forma statements post-ImmunogenX merger

GridAI Technologies Corp.

Amendment adds unaudited pro forma combined statement of operations for three months ended March 31, 2024.
Pro forma combined net loss applicable to common shareholders: $1,894,119.
Pro forma basic loss per share: $1.08; diluted loss per share: $1.08.
Merger with ImmunogenX closed March 13, 2024; Entero is accounting acquirer.
No changes to merger terms or business operations; filing purely supplemental.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.